photosensitizer

Type-I -II Photosensitizer-1 (compound 8b) is a photosensitizer with anticancer properties. It exhibits significant phototoxicity against A549 and 4T1 tumor cells. Under laser irradiation, Type-I -II Photosensitizer-1 demonstrates strong oxygen-independent antitumor activity with an IC50 ranging from 1.50 to 1.76 μM.

Photosensitizer-3, a photosensitizer that generates single-linear oxygen upon near-infrared light excitation in combination with FAP, exhibited potent and selective killing of transfected HEK cells and affibody-targeted A431 cancer cells.

Antitumor photosensitizer-7 (compound 15), a photosensitizer possessing anti-cancer properties, demonstrates substantial cytotoxic effects on the G361 melanoma cell line when exposed to 414 nm blue light irradiation.

Antitumor agent-187 (compound I3), a photosensitizer derived from 5,15-diarylporphyrin, exhibits anticancer activity with a peak absorption wavelength of ~668 nm. This compound induces apoptosis and is applicable in photodynamic therapy (PDP). It selectively accumulates in tumor sites and possesses real-time fluorescence imaging capabilities.

Photosensitizer-5, a photodynamic agent, exhibits cytotoxicity towards HeLa and HepG2 cells, with IC50 values of 10.4 nM and 6.9 nM, respectively. It induces cell death through lipid peroxidation via an iron-independent ferroptosis pathway. Additionally, Photosensitizer-5 displays antitumor activity in HeLa-tumor-bearing mice.

Photosensitizer-6 (Compound 4) is a metal ion complex that inhibits TrxR. It induces apoptosis in 4T1 cells, targeting cancer cells and eliminating tumors through chemophototherapy and immunogenic cell death under illumination. Additionally, Photosensitizer-6 can be utilized for tumor imaging.

Antimicrobial Photosensitizer-1 demonstrates significant potential as an effective agent for treating infections caused by pathogenic microorganisms, with notable antimicrobial efficacy observed in S. aureus-infected mouse wound models [1].

Antitumor Photosensitizer-3 (Compound I), a chlorin derivative, effectively induces apoptosis and necrosis in tumor cells upon exposure to 650 nm laser irradiation. This compound demonstrates reduced skin phototoxicity compared to the positive reference m-THPC in vivo [1].

Photosensitizer-1 (Compound CLB-13) is a photosensitizer [1] .

Photosensitizer-1 (Compound CLB-13) hydrochloride is a photosensitizer [1].

Antitumor Photosensitizer-4 (compound 10b), a conjugate of dasatinib and imatinib, serves as a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. This photosensitizer (PS) induces apoptosis and reactive oxygen species (ROS) production, while demonstrating significant phototoxicity against both HepG2 and B16-F10 cells [1].

Photosensitizer-2 (compound 1), an organic D-π-A sensitizer, exhibits antitumor properties and potent phototoxicity due to an acrylic acid moiety. It demonstrates significant activity against HeLa cells, with IC 50 values of 20.9 ± 4.5 μM (dark) and 0.046 ± 0.012 μM (irradiation) [1].

Compound 11, also known as Antitumor Photosensitizer-2, is a potent photosensitizer with remarkable photodynamic anti-tumor properties and minimal skin photo-toxicity, representing a promising candidate for photodynamic therapy research [1].

Antitumor Photosensitizer-1 (Compound 8) is a potent photosensitizer with remarkable photodynamic anti-tumor properties and minimal skin photo-toxicity, positioning it as a promising new candidate for photodynamic therapy research [1].

Compound PS-I (Photosensitizer-4) is an effective photosensitizer that can efficiently kill cancer cells and inhibit tumor growth under light exposure.

Compound Ru2 (Antitumor photosensitizer-6) exhibits synergistic type I II photosensitization and photocatalytic activities under illumination at 595 nm. It causes oxidative redox imbalance within cells, affecting biosynthesis and metabolic processes, leading to cell apoptosis (Apoptosis). Compound Ru2 is applicable in studies of photodynamic therapy (PDT).

NFh-NMe-2 is a photosensitizer that interacts with nitroreductase (nitroreductase) to generate singlet oxygen in tumor cells, exhibiting cytotoxicity in cancer cells and inducing apoptosis (apoptosis). In mouse models, NFh-NMe-2 demonstrates antitumor activity.

TBC-1 is a chlorophyll-a derivative that acts as a photosensitizer for photodynamic therapy (PDT). It efficiently generates type I ROS and targets the endoplasmic reticulum. TBC-1 demonstrates in vitro biocompatibility and PDT effectiveness under both normoxic and hypoxic conditions.

CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LD). It exhibits phototoxicity against breast cancer cells with an IC50 of 0.01-0.02 μM and demonstrates antitumor efficacy in a 4T1 xenograft mouse model.

TTQ-SA is a near-infrared spiraling aggregation-induced emitter capable of converting near-infrared light (NIR) into thermal energy, resulting in thermal damage and death of tumor cells. In cancer cells MF-7, TTQ-SA shows cell uptake and targeting capabilities. TTQ-SA binds with DNAzyme to inhibit the expression of the survivin gene, enhancing the sensitivity of tumor cells to photothermal therapy.

Verteporfin (BPD-MA) is a YAP inhibitor that inhibits YAP-TEAD interactions. Verteporfin is also a photosensitizer used in photodynamic therapy. Verteporfin also induces apoptosis and inhibits autophagy.

PPA-904, a specific phenothiazine photosensitizer, is used in photodynamic therapy (PDT).

PPA-904 FA is a cationic photosensitizer with broad-spectrum antimicrobial activity for use in photodynamic studies (PDT) studies, which can be used to study chronic leg ulcers and diabetic foot ulcers.

Octocrylene (Octocrilene) is used as an ingredient in sunscreens and cosmetics. This organic compound can penetrate into the skin where it acts as a photosensitizer. This results in an increased production of free radicals under illumination.